Skip to main content

TBC Boehringer Ingelheim Pty Ltd

Product name
TBC
Accepted date
Aug-2023
Active ingredients
empagliflozin, metformin hydrochloride
Proposed indication
As an adjunct to diet and exercise to improve glycaemic control in children aged 10 years and older with type 2 diabetes mellitus.
Application type
C (new medicine)
Publication date
Aug-2023

Help us improve the Therapeutic Goods Administration site